vs
Side-by-side financial comparison of CytomX Therapeutics, Inc. (CTMX) and WINMARK CORP (WINA). Click either name above to swap in a different company.
WINMARK CORP is the larger business by last-quarter revenue ($21.1M vs $18.7M, roughly 1.1× CytomX Therapeutics, Inc.). WINMARK CORP runs the higher net margin — 47.2% vs -0.8%, a 48.1% gap on every dollar of revenue. On growth, WINMARK CORP posted the faster year-over-year revenue change (7.9% vs -25.7%). WINMARK CORP produced more free cash flow last quarter ($8.5M vs $-15.8M). Over the past eight quarters, WINMARK CORP's revenue compounded faster (2.4% CAGR vs -15.9%).
CytomX Therapeutics is a clinical-stage biotechnology company specializing in innovative cancer immunotherapies. It leverages its proprietary Probody technology platform to develop targeted therapies that activate exclusively in tumor microenvironments, minimizing off-target toxicities, with a pipeline covering multiple solid tumor indications and partnerships with leading global pharmaceutical firms.
Winmark Corporation is an American franchisor of five retail businesses that specialize in buying and selling used goods. The company is based in Minneapolis, Minnesota. Winmark was founded in 1988 as Play It Again Sports Franchise Corporation by Ron Olson and Jeffrey Dahlberg after they purchased the Play It Again Sports franchise rights from Martha Morris. They renamed the company to Grow Biz International Inc. in June 1993. Grow Biz went public in August 1993. In 2000, John Morgan replaced...
CTMX vs WINA — Head-to-Head
Income Statement — Q2 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $18.7M | $21.1M |
| Net Profit | $-154.0K | $10.0M |
| Gross Margin | — | — |
| Operating Margin | -6.9% | 61.7% |
| Net Margin | -0.8% | 47.2% |
| Revenue YoY | -25.7% | 7.9% |
| Net Profit YoY | 97.6% | 3.9% |
| EPS (diluted) | — | $2.68 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $21.1M | ||
| Q3 25 | — | $22.6M | ||
| Q2 25 | $18.7M | $20.4M | ||
| Q1 25 | $50.9M | $21.9M | ||
| Q4 24 | $38.1M | $19.5M | ||
| Q3 24 | $33.4M | $21.5M | ||
| Q2 24 | $25.1M | $20.1M | ||
| Q1 24 | $41.5M | $20.1M |
| Q4 25 | — | $10.0M | ||
| Q3 25 | — | $11.1M | ||
| Q2 25 | $-154.0K | $10.6M | ||
| Q1 25 | $23.5M | $10.0M | ||
| Q4 24 | $18.9M | $9.6M | ||
| Q3 24 | $5.7M | $11.1M | ||
| Q2 24 | $-6.5M | $10.4M | ||
| Q1 24 | $13.8M | $8.8M |
| Q4 25 | — | 61.7% | ||
| Q3 25 | — | 65.9% | ||
| Q2 25 | -6.9% | 64.0% | ||
| Q1 25 | 44.4% | 62.0% | ||
| Q4 24 | 46.4% | 65.3% | ||
| Q3 24 | 12.3% | 69.4% | ||
| Q2 24 | -33.7% | 64.7% | ||
| Q1 24 | 28.1% | 60.8% |
| Q4 25 | — | 47.2% | ||
| Q3 25 | — | 49.2% | ||
| Q2 25 | -0.8% | 51.9% | ||
| Q1 25 | 46.2% | 45.4% | ||
| Q4 24 | 49.6% | 49.0% | ||
| Q3 24 | 17.2% | 51.7% | ||
| Q2 24 | -26.0% | 51.8% | ||
| Q1 24 | 33.3% | 43.9% |
| Q4 25 | — | $2.68 | ||
| Q3 25 | — | $3.02 | ||
| Q2 25 | — | $2.89 | ||
| Q1 25 | — | $2.71 | ||
| Q4 24 | — | $2.60 | ||
| Q3 24 | — | $3.03 | ||
| Q2 24 | — | $2.85 | ||
| Q1 24 | — | $2.41 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $49.0M | $10.3M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $119.9M | $-53.7M |
| Total Assets | $175.1M | $24.9M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $10.3M | ||
| Q3 25 | — | $39.7M | ||
| Q2 25 | $49.0M | $28.8M | ||
| Q1 25 | $47.6M | $21.8M | ||
| Q4 24 | $38.1M | $12.2M | ||
| Q3 24 | $40.6M | $37.2M | ||
| Q2 24 | $43.2M | $29.4M | ||
| Q1 24 | $36.2M | $22.9M |
| Q4 25 | — | $-53.7M | ||
| Q3 25 | — | $-26.3M | ||
| Q2 25 | $119.9M | $-36.8M | ||
| Q1 25 | $25.0M | $-45.9M | ||
| Q4 24 | $-456.0K | $-51.0M | ||
| Q3 24 | $-23.5M | $-33.7M | ||
| Q2 24 | $-31.2M | $-42.2M | ||
| Q1 24 | $-31.7M | $-52.6M |
| Q4 25 | — | $24.9M | ||
| Q3 25 | — | $53.7M | ||
| Q2 25 | $175.1M | $43.2M | ||
| Q1 25 | $98.5M | $37.1M | ||
| Q4 24 | $120.5M | $26.8M | ||
| Q3 24 | $139.0M | $52.0M | ||
| Q2 24 | $159.2M | $44.7M | ||
| Q1 24 | $184.7M | $38.3M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-15.8M | $8.5M |
| Free Cash FlowOCF − Capex | $-15.8M | $8.5M |
| FCF MarginFCF / Revenue | -84.6% | 40.3% |
| Capex IntensityCapex / Revenue | 0.1% | 0.1% |
| Cash ConversionOCF / Net Profit | — | 0.86× |
| TTM Free Cash FlowTrailing 4 quarters | $-77.7M | $44.7M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $8.5M | ||
| Q3 25 | — | $12.3M | ||
| Q2 25 | $-15.8M | $9.0M | ||
| Q1 25 | $-21.0M | $15.1M | ||
| Q4 24 | $-19.9M | $8.5M | ||
| Q3 24 | $-20.7M | $12.1M | ||
| Q2 24 | $-19.5M | $8.2M | ||
| Q1 24 | $-26.0M | $13.4M |
| Q4 25 | — | $8.5M | ||
| Q3 25 | — | $12.2M | ||
| Q2 25 | $-15.8M | $9.0M | ||
| Q1 25 | $-21.2M | $15.0M | ||
| Q4 24 | $-20.0M | — | ||
| Q3 24 | $-20.7M | $12.1M | ||
| Q2 24 | $-19.6M | $8.1M | ||
| Q1 24 | $-26.2M | $13.3M |
| Q4 25 | — | 40.3% | ||
| Q3 25 | — | 53.8% | ||
| Q2 25 | -84.6% | 44.0% | ||
| Q1 25 | -41.6% | 68.6% | ||
| Q4 24 | -52.5% | — | ||
| Q3 24 | -62.1% | 56.3% | ||
| Q2 24 | -78.2% | 40.4% | ||
| Q1 24 | -63.1% | 66.0% |
| Q4 25 | — | 0.1% | ||
| Q3 25 | — | 0.3% | ||
| Q2 25 | 0.1% | 0.3% | ||
| Q1 25 | 0.2% | 0.2% | ||
| Q4 24 | 0.2% | 0.0% | ||
| Q3 24 | 0.1% | 0.0% | ||
| Q2 24 | 0.4% | 0.5% | ||
| Q1 24 | 0.3% | 0.4% |
| Q4 25 | — | 0.86× | ||
| Q3 25 | — | 1.10× | ||
| Q2 25 | — | 0.85× | ||
| Q1 25 | -0.89× | 1.51× | ||
| Q4 24 | -1.05× | 0.88× | ||
| Q3 24 | -3.61× | 1.09× | ||
| Q2 24 | — | 0.79× | ||
| Q1 24 | -1.89× | 1.52× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CTMX
| Bristol Myers Squibb Company | $11.6M | 62% |
| Astellas Pharma Inc | $4.6M | 25% |
| Regeneron Pharmaceuticals Inc | $2.1M | 11% |
WINA
Segment breakdown not available.
